Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Coagulation Time and Clot Retraction, Summaries of Pathology

An overview of the howell method, silicone tube method, and slide or drop method for measuring coagulation time of whole blood. It explains the principle behind these methods, which is to determine the length of time required for a measured amount of blood to clot under certain specified conditions. The document also discusses factors affecting coagulation time, such as the presence of circulating anticoagulants, deficiency of coagulation factors, and the influence of calcium, platelets, fibrinogen, and packed cell volume on clot retraction. Additionally, it covers technical errors that may cause hemolysis, the recommended equipment and anticoagulants for hemostasis testing, and the relationship between coagulation tests and coagulation factors. A comprehensive overview of the coagulation process and the various tests used to assess it.

Typology: Summaries

2022/2023

Available from 10/19/2024

noami-anne-cruz
noami-anne-cruz 🇵🇭

3 documents

1 / 12

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
PLATELET COUNT
PLATELETS
Aka “THROMBOCYTES” or
“THROMBOPLASTIDS”
Fragments of megakaryocyte, non-nucleated,
irregular in size
2-4 m in diameter
Life span: 8-11 days in circulation (turnover of
35,000/L/day)
Average count: 150-450 x 109/L
Platelet distribution:
o 2/3 in the circulation
o 1/3 in the spleen
Function:
Hemostasis
o Aggregation and formation of primary
platelet plug
o Thromboplastic activity to initiate clotting
as the source of thromboplastin
o Clot retraction (thrombothenin)
o Maintain capillary integrity
Increase platelet:
o Polcythemia vera
o Idiopathic thrombocythemia
o Chronic myelogenous leukemia
o Splenectomy
Decrease platelet:
o Thrombocytopenia purpura
o Aplastic anemia
o Acute leukemia
o Gaucher’s disease
o Pernicious anemia
o Chemotherapy
o Radiation therapy
Platelets are difficult to count because:
They easily disintegrate
Small, colorless, refractile bodies
Difficult to distinguish from debris
Unevenly distributed in the blood
Have a tendency to clump with each other
***EDTA helps to decrease platelet clumping, but the mean
platelet volume (MPV) will increase during the first hour in
the tube
***BEST to measure MPV 1-3 hours after obtaining the
specimen
METHODS
1. INDIRECT METHOD platelets are counted in relation
to 1000 RBCs in the smear
A. Dameshek method
B. Fonio’s method
C. Olef’s
D. Cramer and Bannerman
E. Modified Indirect Platelet Count
- count platelet in 10 consecutive OIO field and
multiply by 200
2. DIRECT METHOD most accurate way of platelet
count uses RBC pipet, diluting fluid or Unopette for
platelet and WBC count
A. Rees Ecker
B. Guy’s and Leake method
C. Phase Microscopy method (Brecher-Cronkite)
- recommended method
- 1% ammonium oxalate
D. Walker and Sweeney method
E. Unopette method 1:100
F. Van Allen’s method
G. Nygard’s method
H. Tocantin’s method
I. Kristerson as modified by Leiupert
J. Feissly and Ludin method
AUTOMATION:
A. Impedance counting
B. Laser Light scattering
a. Coulter Counter
b. Technicon Hemolab
c. Fisher Autocytometer
d. MK-4 Platelet Counter
Common Artifacts in Automated Platelet Counting
Non-technical factors may produce falsely low
platelet count in instruments but normal in smear
o Platelet cold agglutinins
o Abnormal amount of plasma protein in
various paraproteinemias
o Previous contacts of platelet with foreign
surface such as dialysis membrane
o Giant platelets
o Platelet satellitosis
o Lipemia
o EDTA-induced platelet clumping
Platelet count is low on smear but normal in
instrument (analyzer)
o Patient receiving chemotherapy for acute
leukemia/lymphoma
o White cell cytoplasmic fragments are
counted as platelets
o RBC fragments are counted as platelets
High platelet count may be due to:
o Microspherocytes
o Fragments of leukemic cells
o Pappenheimer bodies
Rees-Ecker
Sodium citrate 3.8g
Brilliant Cresyl Blue 0.1g
Neutral HCHO 0.2mL
Distilled water 100mL
NOTE:
CLUMPS use 0.109 M Sodium Citrate as anticoagulant
and multiply by 1.1
50 platelet 1:20 dilution
platelet 1:200 dilution
REES-ECKER Method:
- count platelet in 25 intermediate squares
= platelet ct x 10 x 200 x 25 (1)
25 OR
- count platelet in 4 large corner squares
= platelet ct x 10 x 200
4 OR
- count platelet in 5 central squares
= platelet ct x 10 x 200 25 (5)
5 OR
- count platelet in each ruled area
= platelet ct x 10 x 200
2
COAGULATION
BLEEDING TIME
Reflects both platelet number and platelet functional
integrity (vascular response to injury)
“global test” – for the adequacy of primary
hemostasis
If standardized, considered the best test
pf3
pf4
pf5
pf8
pf9
pfa

Partial preview of the text

Download Coagulation Time and Clot Retraction and more Summaries Pathology in PDF only on Docsity!

PLATELET COUNT

PLATELETS

  • Aka “THROMBOCYTES” or “THROMBOPLASTIDS”
  • Fragments of megakaryocyte, non-nucleated, irregular in size
  • 2 - 4 m in diameter
  • Life span: 8-11 days in circulation (turnover of 35,000/L/day)
  • Average count: 150-450 x 10^9 /L
  • Platelet distribution: o 2/3 in the circulation o 1/3 in the spleen Function:
  • Hemostasis o Aggregation and formation of primary platelet plug o Thromboplastic activity – to initiate clotting as the source of thromboplastin o Clot retraction (thrombothenin) o Maintain capillary integrity
  • Increase platelet: o Polcythemia vera o Idiopathic thrombocythemia o Chronic myelogenous leukemia o Splenectomy
  • Decrease platelet: o Thrombocytopenia purpura o Aplastic anemia o Acute leukemia o Gaucher’s disease o Pernicious anemia o Chemotherapy o Radiation therapy Platelets are difficult to count because:
  • They easily disintegrate
  • Small, colorless, refractile bodies
  • Difficult to distinguish from debris
  • Unevenly distributed in the blood
  • Have a tendency to clump with each other ***EDTA helps to decrease platelet clumping, but the mean platelet volume (MPV) will increase during the first hour in the tube ***BEST to measure MPV – 1 - 3 hours after obtaining the specimen METHODS
  1. INDIRECT METHOD – platelets are counted in relation to 1000 RBCs in the smear A. Dameshek method B. Fonio’s method C. Olef’s D. Cramer and Bannerman E. Modified Indirect Platelet Count
  • count platelet in 10 consecutive OIO field and multiply by 200
  1. DIRECT METHOD – most accurate way of platelet count uses RBC pipet, diluting fluid or Unopette for platelet and WBC count A. Rees – Ecker B. Guy’s and Leake method C. Phase Microscopy method (Brecher-Cronkite)
  • recommended method
  • 1% ammonium oxalate D. Walker and Sweeney method E. Unopette method – 1: F. Van Allen’s method G. Nygard’s method H. Tocantin’s method I. Kristerson as modified by Leiupert J. Feissly and Ludin method AUTOMATION: A. Impedance counting B. Laser Light scattering a. Coulter Counter b. Technicon Hemolab c. Fisher Autocytometer d. MK-4 Platelet Counter Common Artifacts in Automated Platelet Counting
  • Non-technical factors may produce falsely low platelet count in instruments but normal in smear o Platelet cold agglutinins o Abnormal amount of plasma protein in various paraproteinemias o Previous contacts of platelet with foreign surface such as dialysis membrane o Giant platelets o Platelet satellitosis o Lipemia o EDTA-induced platelet clumping
  • Platelet count is low on smear but normal in instrument (analyzer) o Patient receiving chemotherapy for acute leukemia/lymphoma o White cell cytoplasmic fragments are counted as platelets o RBC fragments are counted as platelets
  • High platelet count may be due to: o Microspherocytes o Fragments of leukemic cells o Pappenheimer bodies Rees-Ecker Sodium citrate – 3.8g Brilliant Cresyl Blue – 0.1g Neutral HCHO – 0.2mL Distilled water – 100mL NOTE: CLUMPS – use 0.109 M Sodium Citrate as anticoagulant and multiply by 1.  50 platelet – 1:20 dilution  platelet – 1:200 dilution REES-ECKER Method:
  • count platelet in 25 intermediate squares = platelet ct x 10 x 200 x 25 (1) 25 OR
  • count platelet in 4 large corner squares = platelet ct x 10 x 200 4 OR
  • count platelet in 5 central squares = platelet ct x 10 x 200 25 (5) 5 OR
  • count platelet in each ruled area = platelet ct x 10 x 200 2 COAGULATION BLEEDING TIME
  • Reflects both platelet number and platelet functional integrity (vascular response to injury)
  • “global test” – for the adequacy of primary hemostasis
  • If standardized, considered the best test
  • Measures the time required for bleeding to stop FACTORS THAT AFFECT BLEEDING TIME
  • Efficiency of tissue fluid to accelerate the clotting
  • Elasticity of the skin
  • Chemical and mechanical actions of platelets FACTORS THAT AFFECT THE RESULT OF BLEEDING TIME
  • Size and shape of the instrument
  • Force applied in setting the injury
  • Depth of the puncture – ideal is 3mm
  • Location, texture and vascularity of area of the skin selected METHODS:
  • DUKE Method (earlobe, 3rd^ or 4th^ finger) o N.V.: 1-5 minutes
  • IVY Method – needs a 40mmhg o (N.V.: 2-9 minutes) o Mielke’s – incision is 9mm long and 1mm deep o Simplate – incision is 5mm long and 1mm deep o Template
  • Copley-Lallitch Immersion (N.V.: 3-6 minutes)
  • Aldelson’s Crosby Immersion Method ASPIRIN TOLERANCE TEST
  • It needs a tablet of Aspirin to produce the bleeding time of a normal individual
  • It takes 2 tablets of aspirin to prolong the bleeding time of a patient with von Willebrand deficiency ACTION OF ASPIRIN
  • inhibits platelet aggregation by:
  • Inhibiting the cyclooxygenase pathway that catalyzes the formation of prostaglandins and thromboxane A
  • Reduces release of endogenous ADP PROLONG BLEEDING TIME ARE MOST FREQUENTLY ASSOCIATED WITH:
  • Prior ingestion of drugs that have an antiplatelet action (ex. Aspirin) – no aspirin intake 7days prior to testing
  • Von Willebrand’s disease
  • Congenital platelet abnormalities
  • Acquired disorders of platelet function (ex. Uremia)
  • Afibrinogenemia
  • Severe dysfibrinogenemia CLOTTING TIME
  • Test to measure all stages in the intrinsic coagulation system and monitor heparin therapy
  • Paul Morawitz – published comprehensive explanation of the chemistry of coagulation
  • The L-W is insensitive to factor deficiencies
  • To assess potential defects in the coagulation cascade, screening tests are first performed (PT, aPTT and TT) Methods:
  1. Slide or Drop Method (NV: 2-6 minutes)
  2. Capillary Method: a. Dale and Laidlaw (NV: 2-4 mins) b. Sabraze’s Method (NV: 3-7 mins)
  3. Venous Blood Method a. WBCT (Whole Blood Clotting Time or Lee-White Clotting Time) b. Howell Method c. Silicone Tube Method SLIDE OR DROP METHOD Principle:
  • Coagulation time of whole blood is the length of time required for a measured amount of blood to clot under certain specified condition. WBCT or LEE-WHITE CLOTTING TIME Principle:
  • The L-W test is based on the fact that when venous blood is put into a glass tube, it will form a solid clot. The time required for this response is a measure of the overall intrinsic and common pathways of coagulation Note:
  • A time-honored procedure to monitor heparin therapy but abandoned currently because of its poor reproducibility
  • When blood is drawn immediately prior to the next dose of heparin, the clotting time should approach the normal range
  • When blood is drawn 1-2 hours after heparin therapy is given or if continuous intravenous route is used, the clotting time should be approximately twice the normal value
  • Prolonged in the presence of circulating anticoagulants (inhibitors) and heparin
  • Show defects in stages of the clotting process Factors affecting coagulation time / Lee-White method
  1. Nature of collecting surface
  2. Diameter of the tube
  3. Temperature
  4. Admixture of blood with tissue juices Prolonged results occur in the following:
  5. Presence of circulating anticoagulants
  6. Deficiency of coagulation factor VIII and IX
  • Factor VII
  • Factor XI Hemolysis
  • Is the release of hemoglobin from ruptured red cells into the plasma Technical Errors that May Cause Hemolysis
  • Excessive stasis through prolonged application of tourniquet
  • Moisture or contamination in the needle, syringe, or blood container
  • Using needles with two small a bore
  • Frothing of sample due to entry of air
  • Expelling blood from the syringe through the needle
  • Excessive and vigorous mixing of blood with the anticoagulant EQUIPMENTS Seraket Tourniquet
  • Recommended tourniquet 20 – gauge needle
  • Most commonly used needle 19 – gauge needle
  • Used for more than 20ml of blood is drawn 21 – gauge needle
  • Used for those with narrow or small veins Silicone-coated evacuated tubes containing the anticoagulant trisodium citrate
  • Used if citrated plasma is required Trisodium Citrate
  • Anticoagulant of choice ANTICOAGULANTS CITRATE
  • Preserves labile clotting factors V and VIII better
  • Most satisfactory for platelet aggregation studies
  • More sensitive to the effects of heparin and therefore preferred for tests to monitor heparin therapy 9:1 (nine parts of blood to one part of AC)
  • Standard ratio for citrate
  • Satisfactory for specimen with relatively normal HCT
  • However, if the HCT value exceeds 0.50 L/L or incomplete filling of the tube, the amount of unbound citrate in the citrate:plasma mixture causes a false prolongation of clotting time, particularly in the Prothrombin Time and Activated Partial Thromboplastin Time tests. EDTA (Ethylenediaminetetraacetic acid)
  • Not a satisfactory AC for coagulation studies because it inhibits the fibrinogen-thrombin reaction
  • Factor V is not stable in it presence HEPARIN
  • An organic acid that acts with anti-thrombin III and inhibits the reactions of all stages of coagulation
  • AC of choice – platelet retention test THREE TECHNIQUES
  • First, adjust the volume of AC used on the basis of the patient’s hematocrit value
  • Time consuming and always means a second venipunture for the patient
  • Formula:
  • Sodium citrate(L) = 0.00185 x blood(mL) x (100-Hct)
  • Second, increase the amount of calcium used to recalcify the plasma in the test system
  • Excess concentrations of calcium ions inhibit coagulation, clotting times may be significantly increased instead of decreases
  • Third, decrease the concentration of the AC
  • Coagulation tests are more sensitive to an excess citrate in the plasma than excess calcium, which occurs with low hematocrits or an overfilled tube.
  • 3.2% (0.109 M) buffered Sodium citrate
  • Standard AC for coagulation studies by NCCLS HEMATOCRIT AND SODIUM CITRATE COLLECTION OF BLOOD TWO-SYRINGE TECHNIQUE
  • SYRINGES
  • EVACUATED TUBES PROCESSING AND HOLDING SAMPLES BEFORE TESTING
  • Once blood is drawn, changes begin to occur in the sample.
  • These changes range from surface activation, which results in shortened clotting times, to increased lability of factors V and VIII, which may lengthen clotting times.
  • Such changes may become significant sources of errors in testing if measures are not taken to minimize and control them when processing and holding samples. Effect of pH
  • Prolongation of clotting time
  • Changes in pH are mediated by the loss of carbon dioxide
  • as the carbon dioxide lost, the pH of the sample increases Effect of Temperature
  • Left at room temperature
  • Deterioration of FV and FVIII
  • At 4˚C
  • Activation of FVII and FXI Centrifugation
  • Platelet-free Plasma is required for coagulation testing
  • Platelet-poor Plasma (PPP)
  • Prepared by centrifugating anticoagulated blood at 2000xg for 10mins
  • Centrifuged samples should be test immediately
  • Or stored at 4˚C for a time not to exceed 2 hours Frozen Samples
  • Samples should not be frozen if testing can be done within 2 hours after collection
  • If freezing is necessary, it should be done rapidly at
  • 20˚C or lower
  • Slow freezing denatures clotting proteins
  • If frozen properly, fibrinogen is stable for at least 4 hours after thawing and survives re-freezing and thawing SPECIMEN COLLECTION AND PROCESSING FOR HEMOSTASIS TESTING Nontraumatic Venipuncture ▪ is the goal anytime blood is drawn Premature activation includes:
  • contamination of the specimen with tissue thromboplastin
  • contact with the surface of an inappropriate specimen container
  • improper temperature
  • hemolysis COMMON COAGULATION TESTS
  • ACTIVATED PARTIAL THROMBOPLASTIN TIME (aPTT)
  • PROTHTOMBIN TIME (PT) Activated Partial Thromboplastin Time (aPTT)
  • Screens abnormalities of the contact factor or instrinsic pathway
  • Used for monitoring unfractionated heparin therapy
  • Considered as the single most useful procedure fro routine screening of coagulation disorders
  • Detects presence of inhibitor
  • Activity of the reagent is similar to that of PF
  • Screens all coagulation factor except FVII and FXIII
  • Time to clot in seconds when contact activator, phospholipids are added to plasma in the presence of calcium
  • Two components of aPTT reagent:
  • Platelet substitute (phospholipid), prepared from brain or plant phospholipids and an activator
  • Kaolin, celite, micronized silica, or ellagic acid are used as the activator
  • Principle:
  • The aPTT measures all factors except VII and XIII. Maximum activation of the contact factors is accomplished by the addition of the activator. Phospholipid is supplied to substitute for PF3.
  • Specimen:
  • Citrated platelet-poor plasma
  • Reagent:
  • Phospholipids with activator and 0.025M CaCl 2
  • Procedure:
  • PPP (0.1ml) is added to 0.1 mL of aPTT reagent and incubated at 37˚C for approximately 3-5minutes. After incubation, 0.1mL of warmed CaCl 2 is added, and the time for clotting to occur is recorded
  • aPTT is reported in seconds
  • Normal range: 20 – 45 seconds
  • Normal control: 25 – 35 seconds
  • Abnormal control: 50 - 70 seconds
  • To differentiate Intrinsic Coagulation Factor Deficiency from the presence of Inhibitors or Circulating AC, repeat the examination

HEMOSTASIS

  • Term used to described the normal functioning of the circulatory system
  • Entire mechanism by which bleeding from an injured blood vessel is spontaneously controlled and stopped STAGES OF HEMOSTASIS
  1. Primary Hemostasis
  • Involved blood vessels and platelets
  • Formation of primary hemostatic plug (platelet plug)
  1. Secondary Hemostasis
  • Involve interaction of coagulation factor
  • Formation of stable fibrin clot
  • Blood factors can be classified as: o Subtrate, substance on which enzyme acts o Zymogen, enzyme precursor o Cofactor, component that aids in the activation of zymogen to active enzyme calcium Coagulation Factors Nomenclature

NOTE:

  • All coagulation factors are produced by the liver except for FVIII:C o vWF – produced by the megakaryocytes and endothelial cells COAGULATION CASCADE CHARACTERISTICS OF COAGULATION FACTORS INHIBITORS OF COAGULATION
  • Protein C – degrades fVa and VIIIa
  • Protein S - degrades fVa and VIIIa
  • Antithrombin III – major inhibitor, also inhibits factors Ixa, Xa, XIa, XIIa, kallikrein and plasmin
  • Heparin cofactor II – inhibit thrombin
  • Alpha-2 macroglobulin – forms a complex with thrombin, kallikrein and plasmin, thus inhibiting their activities
  • Extrinsic pathway inhibitor (EPI)
  • Lipoprotein associated coagulation inhibitor (LACI)
  • Inhibits the VIIa – tissue factor complex
  • C1 inhibitor – inactivator of factor XIIa and kallikrein, it also inhibits factor XIa and plasmin
  • Alpha-1 antitrypsin – inhibitor of thormbin, Xa and XIa DISORDERS OF COAGULATION CAUSING CLOTTING FACTOR DEFICIENCIES CLINICAL MANIFESTATIONS OF COAGULATION FACTOR DEFICIENCIES
  • Alternative:
    • 1% monochloroacetic acid
    • 2% acetic acid
  • Fibrin clot + urea o Normal: Clot is insoluble to urea (24hrs) o FXIII deficiency: clot is soluble to urea (24hrs) Inhibitor Studies ▪ Coagulation testing abnormalities may be caused by either a factor deficiency or an inhibitor. ▪ Patient plasma + normal plasma, which will correct the abnormality caused by a factor deficiency, whereas if the abnormality is secondary to the presence of an inhibitor, the abnormality will not be corrected MIXING STUDIES
  • used to study the cause of a prolonged screening test.
  • study can determine if the cause is a deficiency of one or more factors or an inhibitor.
  • platelet-free, normal plasma that is replete with all coagulation factors (near 100% activity for each) is mixed with the patient's sample. Fibrinogen Group
  • I, V, VIII and XIII
  • Calcium dependent
  • Vit K independent
  • Completely consumed during coagulation
  • Present in plasma but not absent in serum (NO I, V, VIII and XIII Prothrombin Group
  • II, VII, IX and X
  • Calcium dependent
  • Vit K dependent
  • In Vit K dependent, factor depressed: o 1 st^ VII, IX, X, II – last
  • Adsorbable factors o Remove by adsorbing agent (BaSO 4 )
  • Present in plasma and absent in adsorbed plasma Contact Group
  • XII, XI, Prekallikrein, HMWK
  • Calcium dependent
  • Vit K independent
  • Involve in contact phase
  • XII – collagen – XIIa (small amount)
  • Prekallikrein – XIIa – Kallikrein
  • XII – kalliekrein / HWMK – XIIa (large amount)
  • XI – XIIa – Xia
  • Normal PT
  • Prolonged APTT
  • APTT + Fresh plasma – Corrected
  • APTT + Adsorbed plasma – Corrected
  • APTT + Aged serum – Not corrected A. Factor V C. Factor VIII B. Factor VII D. Factor IX
  • Normal PT
  • Prolonged APTT
  • APTT + Fresh plasma – Corrected
  • APTT + Adsorbed plasma – NOT corrected
  • APTT + Aged serum – Corrected A. Factor V C. Factor VIII B. Factor X D. Factor IX
  • Prolonged PT
  • Prolonged APTT
  • APTT + Fresh plasma - Corrected
  • APTT + Adsorbed plasma – Corrected
  • APTT + Aged serum – NOT corrected A. Factor VII C. Factor X B. Factor VIII D. Factor V
  • Prolonged PT
  • Prolonged APTT
  • APTT + Fresh Plasma – Corrected
  • APTT + Adsorbed plasma – NOT corrected
  • APTT + Aged serum – Corrected A. Factor I C. Factor X B. Factor V D. Factor XI
  • Prolonged PT
  • Prolonged APTT
  • PT + Fresh plasma – Corrected
  • PT + Adsorbed plasma – NOT corrected
  • PT + Aged serum – NOT corrected A. Factor I C. Factor X B. Factor V D. Factor II C. Normal PT D. Prolonged APTT E. APTT + Fresh plasma – Corrected F. APTT + Adsorbed plasma – Corrected G. APTT + Aged serum – Corrected CIRCULATING ANTICOAGULANTS
  • Prolonged APTT and PT not corrected
  • Inactivate an activated coagulation factor or block interaction between coagulation factors and platelets
  • Example: Lupus inhibitor
  • Nonspecific anticoagulant
  • IgG, IgM and IgA which interfere with phospholipid portion of the prothrombinase complex
  • TEST: Platelet neutralization procedure
  • Dilute Russell Viper Venom Time 7 – POINT MIXING STUDIES
  • A common coagulation test used to distinguish between a coagulation factor deficiency, a factor inhibitor and lupus anticoagulant.
  • The test is performed when a patient has an unexplained prolongation of a coagulation screening assay, such as the APTT
  • The mixing study is usually done by mixing equal volumes of patient plasma and pooled normal plasma and then repeating the aPTT on the mixture Principle of Mixing Study
  • The basic principle is that the normal plasma contributes a sufficient concentration of clotting factors to “correct” for a factor deficiency. A mixing study that corrects the aPTT is characteristic of factor deficiency, whereas a mixing study that does not correct the aPTT indicates a factor inhibitor. Practices in the Philippines
  • Mix patient’s plasma with normal control plasma (from manufacturer)
  • Immediate mix only
  • If mixing study result is elevated – patient has inhibitor
  • If mixing study result is corrected – patient has factor deficiency Why 7-points? Why not?
  • Easier and real-time identification of cause of problems in APTT or PT results
  • Factor deficiency
  • Presence of Inhibitor
  • Lupus Anticoagulant
  • Expensive and time-consuming 7 Points Dilution
  • Double amount for Fully Automated Analyzers Others
  • Most laboratories perform 7-pointys mixing studies
  • But some laboratories perform 5 or 3 points since no standard is imposed 5 Points Dilution 3 Points Dilution Why not 3 points?
  • 3 points dilution is not recommended because it does not use the 90 and 80 dilution
  • At 90 to 80 dilution , inhibitors are usually detected Types of Mixing Studies
  • IMMEDIATE MIX – the aPTT is performed immediately after mixing the patient plasma and normal plasma, without further incubation. Specimens with fast-reacting factor inhibitors will not correct the immediate mix
  • INCUBATED MIX – aPTT is performed 1 or 2 hours after incubation in 37˚C